These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8889281)

  • 21. Receptor imaging by positron emission tomography and single-photon emission computed tomography.
    Frost JJ
    Invest Radiol; 1992 Dec; 27 Suppl 2():S54-8. PubMed ID: 1334949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia.
    Buchsbaum MS; Hazlett EA
    Schizophr Bull; 1998; 24(3):343-64. PubMed ID: 9718628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neuroimaging in schizophrenia].
    Lanzenberger R; Kasper S
    Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S51-9. PubMed ID: 16270245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuropharmacology and receptor studies in the elderly].
    Meltzer CC
    Rev Neurol; 2002 Oct 16-31; 35(8):767-77. PubMed ID: 12402232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neurotransmitter basis of cognition: psychopharmacological activation studies using positron emission tomography.
    Friston KJ; Grasby PM; Frith CD; Bench CJ; Dolan RJ; Cowen PJ; Liddle PF; Frackowiak RS
    Ciba Found Symp; 1991; 163():76-87; discussion 87-92. PubMed ID: 1687731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuronuclear assessment of patients with epilepsy.
    Goffin K; Dedeurwaerdere S; Van Laere K; Van Paesschen W
    Semin Nucl Med; 2008 Jul; 38(4):227-39. PubMed ID: 18514079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.
    Dewey SL; Smith GS; Logan J; Brodie JD; Simkowitz P; MacGregor RR; Fowler JS; Volkow ND; Wolf AP
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11816-20. PubMed ID: 8265632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography: human brain function and biochemistry.
    Phelps ME; Mazziotta JC
    Science; 1985 May; 228(4701):799-809. PubMed ID: 2860723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neuroimaging--recent issues and future progresses].
    Fukuyama H
    Nihon Ronen Igakkai Zasshi; 2002 Jul; 39(4):364-70. PubMed ID: 12187794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET studies and cholinergic therapy in Alzheimer's disease.
    Nordberg A
    Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET in psychopharmacology.
    Maria Moresco R; Messa C; Lucignani G; Rizzo G G; Todde S; Carla Gilardi M; Grimaldi A; Fazio F
    Pharmacol Res; 2001 Sep; 44(3):151-9. PubMed ID: 11529683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Positron emission tomography. A new measurement method for imaging of regional and biochemical parameters].
    Bolwig TG; Haunsø S; Hove JD; Hesse B; Højgaard L; Jensen M; Paulson OB; Svendsen JH; Sørensen SS
    Ugeskr Laeger; 1994 Oct; 156(43):6341-7. PubMed ID: 7810006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging of neurotransmitter receptors in the living human brain by positron emission tomography (PET).
    Yanai K; Watanabe T; Itoh M; Ido T
    J Nutr Sci Vitaminol (Tokyo); 1992; Spec No():581-4. PubMed ID: 1338452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of cross-species PET imaging to assess neurotransmitter release in brain.
    Finnema SJ; Scheinin M; Shahid M; Lehto J; Borroni E; Bang-Andersen B; Sallinen J; Wong E; Farde L; Halldin C; Grimwood S
    Psychopharmacology (Berl); 2015 Nov; 232(21-22):4129-57. PubMed ID: 25921033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications of neuroreceptor imaging to psychiatry research.
    Smith GS; Koppel J; Goldberg S
    Psychopharmacol Bull; 2003; 37(4):26-65. PubMed ID: 15131516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography in dementia.
    Santens P; Petit H
    Acta Neurol Belg; 1997 Sep; 97(3):192-5. PubMed ID: 9345592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligand-receptor interactions as studied by PET: implications for drug development.
    Hietala J
    Ann Med; 1999 Dec; 31(6):438-43. PubMed ID: 10680859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term stability of neurotransmitter activity investigated with 11C-raclopride PET.
    Schlösser R; Brodie JD; Dewey SL; Alexoff D; Wang GJ; Fowler JS; Volkow N; Logan J; Wolf AP
    Synapse; 1998 Jan; 28(1):66-70. PubMed ID: 9414019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of PET in Parkinson's disease.
    Shinotoh H; Calne DB
    Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron emission tomography in psychiatric disorders.
    Newberg AB; Moss AS; Monti DA; Alavi A
    Ann N Y Acad Sci; 2011 Jun; 1228():E13-25. PubMed ID: 22239386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.